Ursodeoxycholic acid as a potential alternative therapeutic approach for neurodegenerative disorders: Effects on cell apoptosis, oxidative stress and inflammation in the brain
- PMID: 34632427
- PMCID: PMC7611783
- DOI: 10.1016/j.bbih.2021.100348
Ursodeoxycholic acid as a potential alternative therapeutic approach for neurodegenerative disorders: Effects on cell apoptosis, oxidative stress and inflammation in the brain
Abstract
Ursodeoxycholic acid (UDCA) is a bile acid component with anti-apoptotic, anti-oxidant and anti-inflammatory properties. It has been used in clinical medicine for liver diseases for centuries. In neurodegenerative diseases, increased cell apoptosis, oxidative stress and inflammation are frequently observed as well. Due to those beneficial effects of UDCA, recent studies have started to investigate the effects of UDCA in pre-clinical models of neurodegeneration. On this account, I review the data reported so far to investigate the role of UDCA in regulating apoptosis, oxidative stress and inflammation in pre-clinical models of neurodegeneration, as well as in homeostatic state. Evidence have shown that UDCA can reduce apoptosis, inhibit reactive oxygen species and tumor necrosis factor - α production in neurodegenerative models. In addition, UDCA is able to induce apoptosis of brain blastoma cells in homeostatic conditions. Overall, this review suggests the therapeutic potential of UDCA in neurodegenerative disorders, proposing UDCA as a potential alternative therapeutic approach for patients suffering from these diseases.
Keywords: Apoptosis; Inflammation; Neurodegeneration; Oxidative stress; Ursodeoxycholic acid.
Conflict of interest statement
Declarations of interest None.
Similar articles
-
Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients.Liver Int. 2018 Mar;38(3):523-531. doi: 10.1111/liv.13562. Epub 2017 Sep 18. Liver Int. 2018. PMID: 28853202 Free PMC article. Clinical Trial.
-
Ursodeoxycholic acid: a promising therapeutic target for inflammatory bowel diseases?Am J Physiol Gastrointest Liver Physiol. 2019 Dec 1;317(6):G872-G881. doi: 10.1152/ajpgi.00163.2019. Epub 2019 Sep 11. Am J Physiol Gastrointest Liver Physiol. 2019. PMID: 31509435 Review.
-
Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon.Am J Physiol Gastrointest Liver Physiol. 2017 Jun 1;312(6):G550-G558. doi: 10.1152/ajpgi.00256.2016. Epub 2017 Mar 30. Am J Physiol Gastrointest Liver Physiol. 2017. PMID: 28360029
-
The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent.Expert Opin Investig Drugs. 2001 Jul;10(7):1243-53. doi: 10.1517/13543784.10.7.1243. Expert Opin Investig Drugs. 2001. PMID: 11772248 Review.
-
Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production.Mol Med. 1998 Mar;4(3):165-78. Mol Med. 1998. PMID: 9562975 Free PMC article.
Cited by
-
Enzymatic Synthesis of New Acetoacetate-Ursodeoxycholic Acid Hybrids as Potential Therapeutic Agents and Useful Synthetic Scaffolds as Well.Molecules. 2024 Mar 15;29(6):1305. doi: 10.3390/molecules29061305. Molecules. 2024. PMID: 38542941 Free PMC article.
-
Neuroprotection in Parkinson Disease.Neurol Ther. 2025 Jul 18. doi: 10.1007/s40120-025-00793-z. Online ahead of print. Neurol Ther. 2025. PMID: 40679670 Review.
-
Tetrahydroxylated bile acids prevents malignant progression of Barret esophagus in vitro by inhibiting the interleukin-1β-nuclear factor kappa-B pathway.World J Gastroenterol. 2025 Aug 7;31(29):107066. doi: 10.3748/wjg.v31.i29.107066. World J Gastroenterol. 2025. PMID: 40809930 Free PMC article.
-
Cerebral small vessel injury in mice with damage to ACE2-expressing cerebral vascular endothelial cells and post COVID-19 patients.Alzheimers Dement. 2024 Nov;20(11):7971-7988. doi: 10.1002/alz.14279. Epub 2024 Oct 1. Alzheimers Dement. 2024. PMID: 39352003 Free PMC article.
-
Editorial commentary on the special issue emerging psychoneuroimmunology research: Future leaders in focus.Brain Behav Immun Health. 2022 Jan 28;20:100423. doi: 10.1016/j.bbih.2022.100423. eCollection 2022 Mar. Brain Behav Immun Health. 2022. PMID: 35169756 Free PMC article.
References
-
- Abdelkader N.F., Safar M.M., Salem H.A. Ursodeoxycholic acid ameliorates apoptotic cascade in the rotenone model of Parkinson's disease: modulation of mitochondrial perturbations. Mol. Neurobiol. 2016;53:810–817. - PubMed
-
- Beuers U., Boyer J.L., Paumgartner G. Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology. 1998;28:1449–1453. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources